Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock Price
RYTMStock
$86.17−22.50%52W
Market Cap$5.91B
P/E—
PEG Ratio—
Div yield—
Beta2.15
RYTM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.18%
Price vs S&P 500 (4W)-11.48%
VGM Score51.09
RYTM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.83 | -$0.73 | +12.35%(+$0.10) | |
| Q1 2026 | -$0.86 | -$0.83 | +3.61%(+$0.03) | |
| Q4 2025 | -$0.78 | -$0.73 | +6.38%(+$0.05) | |
| Q3 2025 | -$0.73 | -$0.82 | -11.72%(-$0.09) | |
| Q2 2025 | -$0.67 | -$0.75 | -12.11%(-$0.08) |
RYTM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.27
4.27
4.27
4.22
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RYTMRhythm Pharmaceuticals, Inc. Common Stock | F | B | C | 24.7x | 53.5% | 70.9% | — | $86.17 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines for rare neuroendocrine and metabolic disorders. The company commercializes IMCIVREE (setmelanotide), an approved MC4R agonist for treating hyperphagia and severe obesity caused by rare genetic deficiencies in the MC4R pathway. Its pipeline includes two next-generation MC4R agonists designed to avoid hyperpigmentation and candidate therapies for congenital hyperinsulinism.